The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
125056993 12505699 3 F 20160406 20160825 20160628 20160907 EXP GB-MHRA-ADR 23481241 GB-TEVA-669344ACC TEVA 67.00 YR F Y 80.00000 KG 20160907 MD GB GB

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
125056993 12505699 1 PS CIPROFLOXACIN. CIPROFLOXACIN 1 U U 74124
125056993 12505699 2 SS CLEXANE ENOXAPARIN SODIUM 1 Subcutaneous Y U 5SK16 0 120 MG SOLUTION FOR INJECTION QD
125056993 12505699 3 C ADCAL-D3 CALCIUM CARBONATECHOLECALCIFEROL 1 0
125056993 12505699 4 C LETROZOLE. LETROZOLE 1 0
125056993 12505699 5 C OMEPRAZOLE. OMEPRAZOLE 1 0
125056993 12505699 6 C ZOMORPH MORPHINE SULFATE 1 0
125056993 12505699 7 C PERJETA PERTUZUMAB 1 0
125056993 12505699 8 C HERCEPTIN TRASTUZUMAB 1 ONGOING 0 1 DF Q3W
125056993 12505699 9 C PERTUZUMAB PERTUZUMAB 1 ONGOING 0 1 DF Q3W
125056993 12505699 10 C DENOSUMAB DENOSUMAB 1 0 1 DF INJECTION
125056993 12505699 11 C DOCETAXEL. DOCETAXEL 1 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
125056993 12505699 1 Antibiotic therapy
125056993 12505699 2 Peripheral embolism
125056993 12505699 8 Breast cancer stage IV
125056993 12505699 9 Breast cancer stage IV
125056993 12505699 10 Bone disorder
125056993 12505699 11 Breast cancer stage IV

Outcome of event

Event ID CASEID OUTC COD
125056993 12505699 HO
125056993 12505699 LT
125056993 12505699 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
125056993 12505699 Blister
125056993 12505699 Burning sensation
125056993 12505699 Dermatitis
125056993 12505699 Erythema multiforme
125056993 12505699 Pain
125056993 12505699 Protein deficiency
125056993 12505699 Rash erythematous
125056993 12505699 Scab
125056993 12505699 Skin erosion
125056993 12505699 Skin haemorrhage
125056993 12505699 Tachycardia

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
125056993 12505699 2 20160317 20160417 0
125056993 12505699 3 20151016 0
125056993 12505699 11 20160210 0